RxDoctor Payments Data

Terri Kirn, MD

Family Medicine · San Antonio, TXNPI 1770843625

Payments from drug & device makers

$2,745in general payments, 2019–2025

Across 208 payments — averaging $13.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$437
  • Sanofi-aventis U.S. LLC$370
  • Lilly USA, LLC$363
  • Merck$236
  • Sumitomo Pharma America, Inc.$229
  • AbbVie$212
  • plus $897 from 13 others

What the payments were for

  • Food & beverage$2,737100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,745 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$17,574
Medicare patients
69
Services billed
976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide279$381,728
JardianceEmpagliflozin148$233,545
TrulicityDulaglutide80$172,747
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog150$150,374
MounjaroTirzepatide113$144,235
JanuviaSitagliptin Phosphate73$109,392
FarxigaDapagliflozin Propanediol70$92,207
EliquisApixaban60$92,167
MyrbetriqMirabegron75$79,552
GlyxambiEmpagliflozin/Linagliptin58$76,983
GemtesaVibegron74$75,169
RybelsusSemaglutide29$67,957
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog77$50,021
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$48,645
Janumet XrSitagliptin Phos/Metformin Hcl35$44,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$437$449,686308 claims
Boehringer IngelheimJardiance, Glyxambi, Synjardy, Tradjenta$78$351,427232 claims
Lilly USA, LLCTrulicity, Mounjaro$363$316,981193 claims
MerckJanuvia, Janumet Xr, Belsomra, Janumet$236$174,503139 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$127$115,838115 claims
Astellas Pharma US IncMyrbetriq$37$79,55275 claims
Sumitomo Pharma America, Inc.Gemtesa$229$75,16974 claims
GSKTrelegy Ellipta$93$48,64543 claims
Johnson & JohnsonInvega Sustenna, Xarelto$167$48,38527 claims
AbbVieLinzess$212$36,78940 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$370$27,03631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →